Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma. This anal...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur Respir J
Prif Awduron: Bleecker, Eugene R., Wechsler, Michael E., FitzGerald, J. Mark, Menzies-Gow, Andrew, Wu, Yanping, Hirsch, Ian, Goldman, Mitchell, Newbold, Paul, Zangrilli, James G.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: European Respiratory Society 2018
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6203407/
https://ncbi.nlm.nih.gov/pubmed/30139780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00936-2018
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg